BTIG Research Initiates Coverage on Geron Corporation(NASDAQ:GERN). The shares have been rated Neutral. The rating by BTIG Research was issued on Aug 19, 2016.
Geron Corporation (GERN) shares turned negative on Mondays trading session with the shares closing down -0.04 points or -1.48% at a volume of 8,73,712. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.7. The peak price level was also seen at $2.7 while the days lowest was $2.64. Finally the shares closed at $2.66. The 52-week high of the shares is $5.3 while the 52-week low is $2.3. According to the latest information available, the market cap of the company is $423 M.
Geron Corporation(GERN) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $211.00K. Analysts had an estimated revenue of $300.00K. Earnings per share were $-0.05. Analysts had estimated an EPS of $-0.07.
Several Insider Transactions has been reported to the SEC. On Jun 1, 2015, Olivia Kyusuk Bloom (EVP, Chief Financial Officer) sold 2,380 shares at $3.84 per share price.Also, On Jun 1, 2015, Melissa Kelly Behrs (EVP BD and Port&Alliance Mgmt) sold 2,380 shares at $3.84 per share price.On Mar 19, 2015, Thomas Hofstaetter (director) sold 70,000 shares at $4.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor imetelstat in hematologic myeloid malignancies. The Company operates in one segment the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells including malignant progenitor cells to maintain telomere length which provides a capacity for limitless uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR) which binds to the telomere and a catalytic subunit (hTERT) with reverse transcriptase activity which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.